{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:05:10Z","timestamp":1790431510849,"version":"4.1.0"},"reference-count":171,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone turnover markers (BTMs) have become increasingly important in the management of postmenopausal osteoporosis (PMO). In bisphosphonate-treated women with PMO, BTMs can provide early indications of treatment efficacy, are predictors of BMD response and fracture risk reduction, and are potentially useful for monitoring patient compliance. The bone resorption marker serum C-telopeptide cross-link of type 1 collagen (sCTX) has shown high sensitivity and specificity for the detection of increased bone resorption. Recently, sCTX has been singled out as a potential indicator of risk of osteonecrosis of the jaw (ONJ) in patients receiving oral bisphosphonates who require oral surgery. However, whether BTMs are capable of predicting ONJ risk and whether sCTX is usable for this purpose are controversial questions. This article presents an overview of the current literature regarding critical issues affecting the clinical utility of BTMs (including variability and reference ranges) and the current applications of BTMs in PMO management, with a focus on sCTX. Last, the appropriateness of using sCTX to predict ONJ risk in women receiving oral bisphosphonates for PMO is evaluated.<\/jats:p>","DOI":"10.1359\/jbmr.090203","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T18:48:16Z","timestamp":1236106096000},"page":"561-574","source":"Crossref","is-referenced-by-count":122,"title":["Perspective: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw"],"prefix":"10.1093","volume":"24","author":[{"given":"Sanford","family":"Baim","sequence":"first","affiliation":[{"name":"Colorado Center for Bone Research, Lakewood, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D","family":"Miller","sequence":"additional","affiliation":[{"name":"Colorado Center for Bone Research, Lakewood, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020320031052500_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1242\/jcs.113.3.377","article-title":"The cell biology of osteoclast function","volume":"113","author":"Vaananen","year":"2000","journal-title":"J Cell Sci"},{"key":"2024020320031052500_bib2","first-page":"115","article-title":"Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"2024020320031052500_bib3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/clinchem\/45.8.1359","article-title":"Clinical utility of biochemical markers of bone remodeling","volume":"45","author":"Watts","year":"1999","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib4","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","article-title":"Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis","volume":"47","author":"Garnero","year":"2001","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib5","first-page":"439","article-title":"Current and future applications of bone turnover markers","volume":"49","author":"Christgau","year":"2003","journal-title":"Clin Lab (Zaragoza)"},{"key":"2024020320031052500_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/17453679508995567","article-title":"Biochemical markers of bone turnover. A review","volume":"66","author":"Akesson","year":"1995","journal-title":"Acta Orthop Scand"},{"key":"2024020320031052500_bib7","first-page":"97","article-title":"Biochemical markers of bone turnover: Part I: Biochemistry and variability","volume":"26","author":"Seibel","year":"2005","journal-title":"Clin Biochem Rev"},{"key":"2024020320031052500_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01623829","article-title":"Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption","volume":"3","author":"Eastell","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib9","first-page":"333","article-title":"Molecular basis and clinical application of biological markers of bone turnover","volume":"17","author":"Calvo","year":"1996","journal-title":"Endocr Rev"},{"key":"2024020320031052500_bib10","first-page":"34","article-title":"Biochemical markers of bone turnover and their utility in osteoporosis","volume":"36","author":"Caulfield","year":"2004","journal-title":"MLO Med Lab Obs"},{"key":"2024020320031052500_bib11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/clinchem\/41.11.1560","article-title":"Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum","volume":"41","author":"Gomez","year":"1995","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib12","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/clinchem\/36.7.1328","article-title":"Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen","volume":"36","author":"Melkko","year":"1990","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1373\/clinchem.2007.094953","article-title":"Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis","volume":"54","author":"Garnero","year":"2008","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1385\/JCD:2:3:323","article-title":"Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel","volume":"2","author":"Miller","year":"1999","journal-title":"J Clin Densitom"},{"key":"2024020320031052500_bib15","first-page":"785","article-title":"Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers","volume":"34","author":"Withold","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"2024020320031052500_bib16","first-page":"84","article-title":"Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society","volume":"9","author":"North American Menopause Society","year":"2002","journal-title":"Menopause"},{"key":"2024020320031052500_bib17","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1359\/jbmr.2000.15.10.1965","article-title":"Characterization of perimenopausal bone loss: A prospective study","volume":"15","author":"Recker","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib18","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/clinchem\/44.11.2290","article-title":"Clinical evaluation of the serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides","volume":"44","author":"Christgau","year":"1998","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","article-title":"Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy","volume":"26","author":"Christgau","year":"2000","journal-title":"Bone"},{"key":"2024020320031052500_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0003-4266(06)72572-0","article-title":"Practical use of biochemical markers of bone turnover","volume":"67","author":"Kraenzlin","year":"2006","journal-title":"Ann Endocrinol (Paris)"},{"key":"2024020320031052500_bib21","first-page":"780","article-title":"Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320031052500_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jocd.2008.02.004","article-title":"Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naive population","volume":"11","author":"Sebba","year":"2008","journal-title":"J Clin Densitom"},{"key":"2024020320031052500_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib24","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"2024020320031052500_bib25","first-page":"5","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: A challenge, a responsibility, and an opportunity","volume":"28","author":"Marx","year":"2008","journal-title":"Int J Periodontics Restorative Dent"},{"key":"2024020320031052500_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.coms.2007.07.003","article-title":"Bisphosphonates and bisphosphonate induced osteonecrosis","volume":"19","author":"Sawatari","year":"2007","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"2024020320031052500_bib27","first-page":"510","article-title":"Bisphosphonates and the dental patient: Part 2","volume":"28","author":"Zak","year":"2007","journal-title":"Compend Contin Educ Dent"},{"key":"2024020320031052500_bib28","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.joms.2008.01.054","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"66","author":"Khosla","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"issue":"Suppl 1","key":"2024020320031052500_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01621873","article-title":"Biochemical markers of bone turnover for the clinical investigation of osteoporosis","volume":"3","author":"Delmas","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib30","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/clinchem\/47.8.1443","article-title":"Interlaboratory variation of biochemical markers of bone turnover","volume":"47","author":"Seibel","year":"2001","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00228-006-0174-3","article-title":"An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice","volume":"62","author":"Leeming","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"2024020320031052500_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0889-8529(05)70007-4","article-title":"Biochemical markers of bone turnover. Applications for osteoporosis","volume":"27","author":"Garnero","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2024020320031052500_bib33","first-page":"118","article-title":"Type I collagen C-telopeptide degradation products as bone resorption markers","volume":"21","author":"Pedersen","year":"1998","journal-title":"Clin Ligand Assay"},{"key":"2024020320031052500_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"2024020320031052500_bib35","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1074\/jbc.272.15.9755","article-title":"Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region","volume":"272","author":"Fledelius","year":"1997","journal-title":"J Biol Chem"},{"key":"2024020320031052500_bib36","volume-title":"Serum CrossLaps ELISA [package insert]","author":"Nordic Bioscience Diagnostics","year":"2002"},{"key":"2024020320031052500_bib37","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/clinchem\/40.11.2022","article-title":"Immunoassay for quantifying type I collagen degradation products in urine evaluated","volume":"40","author":"Bonde","year":"1994","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib38","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/clinchem\/43.9.1570","article-title":"Comparison of analytical performance and biological variability of three bone resorption assays","volume":"43","author":"Ju","year":"1997","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0009-8981(00)00285-0","article-title":"Biological variability in assessing the clinical value of biochemical markers of bone turnover","volume":"299","author":"Plebani","year":"2000","journal-title":"Clin Chim Acta"},{"key":"2024020320031052500_bib40","first-page":"579","article-title":"Long-term variability of bone turnover markers in patients with non-metastatic breast cancer","volume":"48","author":"Seibel","year":"2002","journal-title":"Clin Lab (Zaragoza)"},{"key":"2024020320031052500_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1081\/ERC-120015063","article-title":"Biological variability of biochemical markers of bone turnover in healthy women","volume":"28","author":"Takahashi","year":"2002","journal-title":"Endocr Res"},{"key":"2024020320031052500_bib42","first-page":"91","article-title":"The use of biochemical markers of bone turnover in osteoporosis","volume":"26","author":"Allende-Vigo","year":"2007","journal-title":"P R Health Sci J"},{"key":"2024020320031052500_bib43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/000456329703400501","article-title":"The performance and utility of biochemical markers of bone turnover: Do we know enough to use them in clinical practice","volume":"34","author":"Blumsohn","year":"1997","journal-title":"Ann Clin Biochem"},{"key":"2024020320031052500_bib44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/clinchem\/41.8.1195","article-title":"Effect of light and gamma-irradiation on pyridinolines and telopeptides of type I collagen in urine","volume":"41","author":"Blumsohn","year":"1995","journal-title":"Clin Chem"},{"key":"2024020320031052500_bib45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1046\/j.1365-2362.1996.460602.x","article-title":"To determine the effects of ultraviolet light, natural light and ionizing radiation on pyridinium cross-links in bone and urine using high-performance liquid chromatography","volume":"26","author":"Colwell","year":"1996","journal-title":"Eur J Clin Invest"},{"key":"2024020320031052500_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cccn.2004.07.024","article-title":"Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years","volume":"350","author":"Qvist","year":"2004","journal-title":"Clin Chim Acta"},{"key":"2024020320031052500_bib47","volume-title":"Quidel Metra BAP EIA Kit [package insert]","author":"Quidel","year":"2002"},{"key":"2024020320031052500_bib48","author":"Roche Diagnostics"},{"key":"2024020320031052500_bib49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-0029-1211967","article-title":"Automated and manual assays for urinary crosslinks of collagen: Which assay to use","volume":"106","author":"Seibel","year":"1998","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"Suppl 6","key":"2024020320031052500_bib50","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","article-title":"Preanalytical variability of biochemical markers of bone turnover","volume":"11","author":"Hannon","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"key":"2024020320031052500_bib52","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","article-title":"Effect of feeding on bone turnover markers and its impact on biological variability of measurements","volume":"30","author":"Clowes","year":"2002","journal-title":"Bone"},{"key":"2024020320031052500_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02390836","article-title":"The relation between lifestyle factors and biochemical markers of bone turnover among early postmenopausal women","volume":"68","author":"Hla","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"2024020320031052500_bib54","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1359\/jbmr.1999.14.4.609","article-title":"Changes in bone resorption during the menstrual cycle","volume":"14","author":"Chiu","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib55","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1530\/eje.0.1400332","article-title":"Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption","volume":"140","author":"Schlemmer","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"2024020320031052500_bib56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","author":"Glover","year":"2008","journal-title":"Bone"},{"key":"2024020320031052500_bib57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/clinchem\/46.3.431a","article-title":"Circadian variation in serum CrossLaps concentration is reduced in fasting individuals","volume":"46","author":"Christgau","year":"2000","journal-title":"Clin Chem"},{"issue":"Suppl 6","key":"2024020320031052500_bib58","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","article-title":"The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1359\/jbmr.080703","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA","volume":"24","author":"Glover","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib60","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bone.2007.01.008","article-title":"A cross-sectional study of bone turnover markers in healthy premenopausal women","volume":"40","author":"de Papp","year":"2007","journal-title":"Bone"},{"key":"2024020320031052500_bib61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-008-9126-5","article-title":"Determinants of bone turnover markers in healthy premenopausal women","volume":"82","author":"Adami","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"2024020320031052500_bib62","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1185\/030079905X49635","article-title":"Clinical use of serum and urine bone markers in the management of osteoporosis","volume":"21","author":"Srivastava","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2024020320031052500_bib63","author":"National Osteoporosis Foundation","year":"2008"},{"key":"2024020320031052500_bib64","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/PL00004183","article-title":"Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy","volume":"11","author":"Fink","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib65","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1359\/jbmr.2003.18.10.1789","article-title":"Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: The OFELY study","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib66","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0009-9120(01)00273-9","article-title":"Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women","volume":"34","author":"Scariano","year":"2001","journal-title":"Clin Biochem"},{"key":"2024020320031052500_bib67","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001980070088","article-title":"Clinical use of biochemical markers of bone remodeling: Current status and future directions","volume":"11","author":"Looker","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF01774016","article-title":"Accurate assessment of precision errors: How to measure the reproducibility of bone densitometry techniques","volume":"5","author":"Gluer","year":"1995","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib69","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-59259-659-1_11","volume-title":"Bone Densitometry in Clinical Practice: Application and Interpretation","author":"Bonnick","year":"2004","edition":"2nd ed"},{"key":"2024020320031052500_bib70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1385\/JCD:8:4:371","article-title":"Precision assessment and radiation safety for dual-energy X-ray absorptiometry: Position paper of the International Society for Clinical Densitometry","volume":"8","author":"Baim","year":"2005","journal-title":"J Clin Densitom"},{"key":"2024020320031052500_bib71","first-page":"S416","article-title":"Reproducibility of biochemical markers of bone turnover in clinical practice","volume":"22","author":"Schafer","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"Suppl 6","key":"2024020320031052500_bib72","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1007\/s001980070006","article-title":"Markers of bone turnover for the prediction of fracture risk","volume":"11","author":"Garnero","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib73","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib74","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1359\/jbmr.1999.14.9.1614","article-title":"Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study","volume":"14","author":"Garnero","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib75","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","article-title":"Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320031052500_bib76","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1507\/endocrj.52.667","article-title":"Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis","volume":"52","author":"Kim","year":"2005","journal-title":"Endocr J"},{"key":"2024020320031052500_bib77","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"key":"2024020320031052500_bib78","first-page":"2363","article-title":"Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study","volume":"84","author":"Ravn","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320031052500_bib79","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(03)00168-6","article-title":"Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis","volume":"33","author":"Ravn","year":"2003","journal-title":"Bone"},{"key":"2024020320031052500_bib80","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib81","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib82","first-page":"S374","article-title":"A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: The IMPACT study","volume":"18","author":"Delmas","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib83","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01880414","article-title":"Screening procedure for women at risk of developing postmenopausal osteoporosis","volume":"1","author":"Christiansen","year":"1990","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib84","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s002239900135","article-title":"Biochemical markers of bone turnover reflect femoral bone loss in elderly women","volume":"59","author":"Dresner-Pollak","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2024020320031052500_bib85","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(87)91671-0","article-title":"Prediction of rapid bone loss in postmenopausal women","volume":"1","author":"Christiansen","year":"1987","journal-title":"Lancet"},{"key":"2024020320031052500_bib86","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00198-007-0379-z","article-title":"Prediction of bone loss using biochemical markers of bone turnover","volume":"18","author":"Lenora","year":"2007","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib87","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1359\/jbmr.2000.15.7.1398","article-title":"Biochemical markers as predictors of rates of bone loss after menopause","volume":"15","author":"Rogers","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib88","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1359\/jbmr.1997.12.7.1083","article-title":"Relationship of bone turnover to bone density and fractures","volume":"12","author":"Melton","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib89","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib90","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1359\/JBMR.050609","article-title":"Identification of osteopenic women at high risk of fracture: The OFELY study","volume":"20","author":"Sornay-Rendu","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib91","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from BONE","volume":"21","author":"Chesnut","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2024020320031052500_bib92","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib93","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024020320031052500_bib94","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"2024020320031052500_bib95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","article-title":"Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis","volume":"42","author":"Delmas","year":"2008","journal-title":"Bone"},{"key":"2024020320031052500_bib96","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024020320031052500_bib97","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib98","author":"Division of Metabolic and Endocrine Drug Products-U.S. Food and Drug Administration","year":"1994"},{"key":"2024020320031052500_bib99","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1359\/jbmr.070905","article-title":"Recommendations for the clinical evaluation of agents for treatment of osteoporosis: Consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF)","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","article-title":"Importance of precision in bone density measurements","volume":"4","author":"Bonnick","year":"2001","journal-title":"J Clin Densitom"},{"key":"2024020320031052500_bib101","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jocd.2006.05.002","article-title":"Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference","volume":"9","author":"Binkley","year":"2006","journal-title":"J Clin Densitom"},{"key":"2024020320031052500_bib102","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s001980070083","article-title":"Short-term risedronate treatment in postmenopausal women: Effects on biochemical markers of bone turnover","volume":"11","author":"Raisz","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib103","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF02938621","article-title":"Monitoring osteoporosis therapies","volume":"5","author":"Miller","year":"2007","journal-title":"Curr Osteoporos Rep"},{"key":"2024020320031052500_bib104","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.bone.2008.01.021","article-title":"Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy","volume":"42","author":"Reginster","year":"2008","journal-title":"Bone"},{"key":"2024020320031052500_bib105","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib106","first-page":"3537","article-title":"Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women","volume":"85","author":"Greenspan","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320031052500_bib107","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1359\/jbmr.080320","article-title":"Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapy","volume":"23","author":"Bauer","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib108","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1359\/jbmr.080321","article-title":"Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapy","volume":"23","author":"Eastell","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib109","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","article-title":"Adherence, patient preference and dosing frequency: Understanding the relationship","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone"},{"key":"2024020320031052500_bib110","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","article-title":"Compliance with drug therapy for postmenopausal osteoporosis","volume":"17","author":"Weycker","year":"2006","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib111","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.amjmed.2005.12.021","article-title":"Approaches to patient education: Emphasizing the long-term value of compliance and persistence","volume":"119","author":"Gold","year":"2006","journal-title":"Am J Med"},{"key":"2024020320031052500_bib112","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 6","key":"2024020320031052500_bib113","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/s001980070007","article-title":"Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib114","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320031052500_bib115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11154-006-9008-y","article-title":"Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates","volume":"7","author":"Chaiamnuay","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"key":"2024020320031052500_bib116","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws-American Association of Oral and Maxillofacial Surgeons","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"2024020320031052500_bib117","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib118","first-page":"1391","article-title":"Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw","volume":"35","author":"Khan","year":"2008","journal-title":"J Rheumatol"},{"key":"2024020320031052500_bib119","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","article-title":"Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations","volume":"137","author":"American Dental Association Council on Scientific Affairs","year":"2006","journal-title":"J Am Dent Assoc"},{"key":"2024020320031052500_bib120","first-page":"71","article-title":"Persistent painful ulcer of the posterior lingual mandibular mucosa","volume":"4","author":"Peters","year":"2003","journal-title":"J Contemp Dent Pract"},{"key":"2024020320031052500_bib121","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1834-7819.2003.tb00011.x","article-title":"Oral ulceration with bone sequestration","volume":"48","author":"Farah","year":"2003","journal-title":"Aust Dent J"},{"key":"2024020320031052500_bib122","first-page":"198","article-title":"Oral and maxillofacial pathology case of the month. Lingual mandibular sequestration with ulceration","volume":"122","author":"Kessler","year":"2005","journal-title":"Tex Dent J"},{"key":"2024020320031052500_bib123","first-page":"276","volume-title":"Oral and Maxillofacial Pathology","author":"Neville","edition":"3rd ed."},{"key":"2024020320031052500_bib124","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.bdj.4801315","article-title":"Oral ulceration: A new and unusual complication","volume":"192","author":"Scully","year":"2002","journal-title":"Br Dent J"},{"key":"2024020320031052500_bib125","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1902\/jop.1997.68.8.758","article-title":"Spontaneous bony exposure: A report of 4 cases of idiopathic exposure and sequestration of alveolar bone","volume":"68","author":"Sonnier","year":"1997","journal-title":"J Periodontol"},{"key":"2024020320031052500_bib126","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","article-title":"A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteristics","volume":"29","author":"Pazianas","year":"2007","journal-title":"Clin Ther"},{"key":"2024020320031052500_bib127","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib128","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000106451","article-title":"A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer","volume":"71","author":"Goldman","year":"2006","journal-title":"Oncology"},{"key":"2024020320031052500_bib129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00520-006-0120-z","article-title":"Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis","volume":"15","author":"Walter","year":"2007","journal-title":"Support Care Cancer"},{"key":"2024020320031052500_bib130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.14219\/jada.archive.2006.0350","article-title":"Osteonecrosis of the jaw and oral bisphosphonate treatment","volume":"137","author":"Nase","year":"2006","journal-title":"J Am Dent Assoc"},{"key":"2024020320031052500_bib131","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2006.11.023","article-title":"Jaw osteonecrosis related to bisphosphonate therapy: A severe secondary disorder","volume":"40","author":"Dannemann","year":"2007","journal-title":"Bone"},{"key":"2024020320031052500_bib132","volume-title":"Zometa (zoledronic acid) [US prescribing information]","author":"Novartis Pharmaceuticals","year":"2008"},{"key":"2024020320031052500_bib133","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2024020320031052500_bib134","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"2024020320031052500_bib135","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024020320031052500_bib136","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5694\/j.1326-5377.2005.tb06761.x","article-title":"Bisphosphonates and avascular necrosis of the jaw: A possible association","volume":"182","author":"Carter","year":"2005","journal-title":"Med J Aust"},{"key":"2024020320031052500_bib137","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"2024020320031052500_bib138","author":"ICD-9-CM Index to Diseases Addenda (FY08) Centers of Disease Control and Prevention website"},{"key":"2024020320031052500_bib139","first-page":"S212","article-title":"Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from Diva","volume":"17","author":"Eisman","year":"2006","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib140","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024020320031052500_bib141","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2024020320031052500_bib142","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1359\/jbmr.060712","article-title":"Osteonecrosis of the jaw: More research needed","volume":"21","author":"Shane","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib143","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","article-title":"Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people","volume":"139","author":"Cartsos","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"2024020320031052500_bib144","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.joms.2006.02.011","article-title":"Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis","volume":"64","author":"Zavras","year":"2006","journal-title":"J Oral Maxillofac Surg"},{"key":"2024020320031052500_bib145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00198-007-0502-1","article-title":"Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker","volume":"19","author":"Pazianas","year":"2008","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib146","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.joms.2007.12.048","article-title":"Serum CTX testing","volume":"66","author":"Schwartz","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"2024020320031052500_bib147","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"2024020320031052500_bib148","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10067-007-0824-6","article-title":"Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long-term extension","volume":"27","author":"Stakkestad","year":"2008","journal-title":"Clin Rheumatol"},{"key":"2024020320031052500_bib149","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","article-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density","volume":"40","author":"Saag","year":"2007","journal-title":"Bone"},{"key":"2024020320031052500_bib150","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years","volume":"91","author":"Bonnick","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320031052500_bib151","first-page":"853","article-title":"Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: Implications from clinical studies with ibandronate","volume":"66","author":"Papapoulos","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2024020320031052500_bib152","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2024020320031052500_bib153","first-page":"S69","article-title":"Osteonecrosis of the jaw: Zoledronic acid 5 mg experience in a variety of osteoporosis indications","volume":"23","author":"Grbic","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib154","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S8756-3282(98)00044-1","article-title":"Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment","volume":"22","author":"Ravn","year":"1998","journal-title":"Bone"},{"key":"2024020320031052500_bib155","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib156","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib157","first-page":"S281","article-title":"Change in bone turnover markers following discontinuation of long-term alendronate in FLEX","volume":"20","author":"Schwartz","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib158","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","article-title":"Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holiday","volume":"19","author":"Curtis","year":"2008","journal-title":"Osteoporos Int"},{"key":"2024020320031052500_bib159","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1600-051X.1995.tb01793.x","article-title":"Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs","volume":"22","author":"Giannobile","year":"1995","journal-title":"J Clin Periodontol"},{"key":"2024020320031052500_bib160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1034\/j.1600-0501.1996.090602.x","article-title":"C-telopeptide pyridinoline cross-links (ICTP) and periodontal pathogens associated with endosseous oral implants","volume":"9","author":"Oringer","year":"1998","journal-title":"Clin Oral Implants Res"},{"key":"2024020320031052500_bib161","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1600-051X.1998.tb02383.x","article-title":"Relationship between C-telopeptide pyridinoline cross-links (ICTP) and putative periodontal pathogens in periodontitis","volume":"25","author":"Palys","year":"1998","journal-title":"J Clin Periodontol"},{"key":"2024020320031052500_bib162","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1749-6632.1999.tb07698.x","article-title":"C-telopeptide pyridinoline cross-links. Sensitive indicators of periodontal tissue destruction","volume":"878","author":"Giannobile","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"2024020320031052500_bib163","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1902\/jop.2001.72.8.1045","article-title":"Effect of non-surgical periodontal therapy on C-telopeptide pyridinoline cross-links (ICTP) and interleukin-1 levels","volume":"72","author":"Al-Shammari","year":"2001","journal-title":"J Periodontol"},{"key":"2024020320031052500_bib164","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5","article-title":"Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease","volume":"41","author":"Garnero","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"S2","key":"2024020320031052500_bib165","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jbmr.5650140213","article-title":"Biochemical markers of bone turnover in Paget's disease of bone","volume":"14","author":"Delmas","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib166","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S8756-3282(01)00592-0","article-title":"Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease","volume":"29","author":"Alvarez","year":"2001","journal-title":"Bone"},{"key":"2024020320031052500_bib167","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s007740200016","article-title":"Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: Evolution after antiresorptive therapy","volume":"20","author":"Peris","year":"2002","journal-title":"J Bone Miner Metab"},{"key":"2024020320031052500_bib168","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1359\/JBMR.041212","article-title":"Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone","volume":"20","author":"Alexandersen","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"S2","key":"2024020320031052500_bib169","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1359\/jbmr.06s204","article-title":"Biochemical assessment of Paget's disease of bone","volume":"21","author":"Shankar","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1359\/JBMR.041111","article-title":"An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone","volume":"20","author":"Collins","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020320031052500_bib171","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment","volume":"35","author":"Chapurlat","year":"2004","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.090203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/4\/561\/56575527\/5650240401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/4\/561\/56575527\/5650240401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T23:58:01Z","timestamp":1738972681000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/24\/4\/561-574\/7599957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":171,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.090203","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,4,1]]},"published":{"date-parts":[[2009,4,1]]}}}